You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 21, 2025

Drug Sales Trends for METFORMIN


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for METFORMIN (2021)

Revenues by Pharmacy Type

Pharmacy Type Revenues
MAIL-ORDER $301,371,116
INSIDE ANOTHER STORE $274,491,825
[disabled in preview] $754,966,824
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
MAIL-ORDER 8,959,071
INSIDE ANOTHER STORE 24,548,804
[disabled in preview] 54,494,760
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $158,282,540
MEDICARE $407,048,660
[disabled in preview] $767,885,513
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for METFORMIN
Drug Units Sold Trends for METFORMIN

Market Analysis and Sales Projections for Metformin

Introduction to Metformin

Metformin is a widely used oral antidiabetic drug in the treatment of type 2 diabetes. It works by lowering blood sugar levels, promoting weight loss, improving insulin sensitivity, and potentially offering cardiovascular benefits. The global metformin market is experiencing significant growth, driven by several key factors.

Current Market Size and Growth

As of 2023, the global metformin market size was valued at $3.91 billion and is expected to grow to $4.17 billion in 2024, with a compound annual growth rate (CAGR) of 6.7%[1].

By 2028, the market is projected to reach $5.5 billion, growing at a CAGR of 7.2% from 2023 to 2028. This robust growth is attributed to the increasing prevalence of diabetes, expansion into emerging markets, and heightened awareness and adoption of metformin globally[1].

Drivers of the Market

Several factors are driving the growth of the metformin market:

  • Increasing Prevalence of Diabetes: The global prevalence of diabetes is on the rise, with approximately 537 million adults aged 20-79 having diabetes in 2021, projected to increase to 643 million by 2030 and 783 million by 2045[1].
  • Heightened Awareness and Healthcare Spending: Increased awareness about diabetes management and rising healthcare spending aimed at addressing diabetes-related care are significant drivers[1].
  • Aging Population: The aging population, which requires more diabetes management, is another key factor[1].
  • Generic Competition and Combination Therapies: The expiry of patents leading to generic competition and the rising demand for combination therapies also contribute to market growth[1].

Market Segmentation

The metformin market is segmented based on several criteria:

  • Product Type: Standard-release tablets and slow-release tablets are the primary product types. Slow-release tablets are gaining popularity due to their convenience and reduced side effects[2].
  • Dosage Type: Common dosages include 500mg, 750mg, 850mg, and 1g. The choice of dosage often depends on the patient's condition and response to the medication[2].
  • End-Users: Clinics, hospitals, homecare, and other end-users are the main segments. Homecare is a growing segment due to the increasing preference for self-management of diabetes[2].
  • Distribution Channels: Hospital pharmacy, retail pharmacy, online pharmacy, and others are the key distribution channels. Online pharmacies are becoming more popular due to convenience and accessibility[2].

Regional Analysis

The metformin market is diverse across different regions:

  • North America: The USA and Canada are significant markets, with the USA showing strong growth due to high healthcare spending and a large diabetic population[1][2].
  • Europe: Europe is another major market, with countries like Germany, the UK, and Italy contributing significantly to the regional market size[5].
  • Asia Pacific: This region, particularly countries like India, China, and Japan, is experiencing rapid growth due to a large and growing diabetic population and increasing healthcare infrastructure[1][5].
  • South America: Countries in South America are also seeing growth, driven by increasing awareness and healthcare spending[1].

Competitive Landscape

The metformin market is highly competitive, with several key players:

  • Major Manufacturers: Companies like Keyuan Pharmaceutical, Aarti Drugs, and Shijiazhuang Polee Pharmaceutical are among the top manufacturers, with Keyuan Pharmaceutical holding a significant market share[4][5].
  • Generic Competition: The market is also seeing increased competition from generic manufacturers, which is driving down prices and increasing accessibility[1].

Trends and Strategies

Several trends are shaping the future of the metformin market:

  • New Formulations and Products: The introduction of new metformin products and formulations is expected to enhance treatment options and patient compliance[1].
  • Lifestyle Interventions: There is an increasing emphasis on lifestyle interventions to manage diabetes, which complements the use of metformin[1].
  • Research and Development: Ongoing R&D efforts are focused on enhancing treatment options and addressing potential side effects and safety concerns[1].
  • Partnerships and Collaborations: Growing partnerships among pharmaceutical companies and healthcare providers are aimed at improving patient care and outcomes[1].

Challenges and Restraints

Despite the growth, the metformin market faces some challenges:

  • Side Effects and Safety Concerns: Metformin and combination therapies like Metformin-Pioglitazone come with potential side effects and FDA black box warnings, which can discourage some patients from using these medications[3].
  • Regulatory Framework: Strict regulatory frameworks and pricing pressures can also impact market growth[2].

Future Outlook

By 2030, the metformin market is expected to continue its strong growth trajectory:

  • Market Size Projections: The market is projected to reach USD 6,420.02 billion by 2030, growing at a CAGR of 6.0% from 2023 to 2030[2].
  • Growth Strategies: Market trend-based strategies, competitor strategies, and innovations in manufacturing technology will be crucial for future growth[1].

Key Takeaways

  • The global metformin market is driven by the increasing prevalence of diabetes, heightened awareness, and expanding healthcare spending.
  • The market is segmented by product type, dosage, end-users, and distribution channels.
  • Regional growth is significant in North America, Europe, and the Asia Pacific.
  • New formulations, lifestyle interventions, and R&D efforts are key trends.
  • Despite challenges, the market is expected to grow significantly by 2030.

Frequently Asked Questions (FAQs)

Q1: What is the current market size of the global metformin market? The global metformin market size was valued at $3.91 billion in 2023[1].

Q2: What is the projected growth rate of the metformin market from 2023 to 2028? The metformin market is expected to grow at a CAGR of 7.2% from 2023 to 2028[1].

Q3: Which regions are the largest markets for metformin? North America, Europe, and the Asia Pacific are the largest markets for metformin, with the Asia Pacific region showing rapid growth[1][5].

Q4: What are the main drivers of the metformin market? The main drivers include the increasing prevalence of diabetes, heightened awareness and healthcare spending, and the aging population requiring diabetes management[1].

Q5: What are some of the challenges facing the metformin market? Challenges include potential side effects and safety concerns, as well as strict regulatory frameworks and pricing pressures[3].

Cited Sources

  1. Research and Markets: Metformin Global Market Size, Competitors, Trends & Forecast[1].
  2. Data Bridge Market Research: Metformin Market Size, Share, Statistics & Industry Forecast By 2030[2].
  3. Verified Market Research: Metformin-Pioglitazon Market Size, Share, Trends, Scope & Forecast[3].
  4. Valuates Reports: Global Metformin Hydrochloride Market Research Report 2024[4].
  5. QYResearch: Global Metformin Hydrochloride Market Insights, Forecast to 2030[5].
Last updated: 2024-12-31

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.